Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.

CEO

Dr. Francois R. Martelet M.D.

Employees

Country

Sweden

ISIN

SE0000722365

Listings

0 Comments

Share your thoughts

FAQ

What is Vivesto AB stock price today?▼

The current price of OMAX.STU is €0 EUR — it has decreased by -0% in the past 24 hours. Watch Vivesto AB stock price performance more closely on the chart.

What is Vivesto AB stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Vivesto AB stocks are traded under the ticker OMAX.STU.

Is Vivesto AB stock price growing?▼

OMAX.STU stock has fallen by -9.09% compared to the previous week, the month change is a -16.67% fall, over the last year Vivesto AB has showed a -87.34% decrease.

How many employees does Vivesto AB have?▼

As of April 11, 2026, the company has 19 employees.

In which sector is Vivesto AB located?▼

Vivesto AB operates in the Energy sector.

When did Vivesto AB complete a stock split?▼

Vivesto AB has not had any recent stock splits.

Where is Vivesto AB headquartered?▼

Vivesto AB is headquartered in Solna, Sweden.